SCHEMBL4132068

SCHEMBL4132068

Cc1ccccc1N=C1NC(=O)C(C(C)c2cccc(C(F)(F)F)c2)S1

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 4/20 0.49
GAA P10253 2/20 0.41
MEN1 O00255 1/20 0.41
ALDH1A1 P00352 1/20 0.41
KMT2A Q03164 1/20 0.41
USP2 O75604 1/20 0.38
DAO P14920 1/20 0.37
GRIN2B Q13224 1/20 0.36
KCNN4 O15554 1/20 0.33
ACP3 P15309 1/20 0.33
RXFP1 Q9HBX9 1/20 0.33
KDM4E B2RXH2 1/20 0.33
HSD17B2 P37059 1/20 0.32
GALR3 O60755 1/20 0.32
NPC1 O15118 1/20 0.32
LMNA P02545 1/20 0.32
TP53 P04637 1/20 0.32
RAB9A P51151 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4132065 0.84 TP53 (0.45) HSD11B1GAAALDH1A1DAOKCNN4
SCHEMBL4132066 0.84 TP53 (0.45) HSD11B1GAAALDH1A1DAOKCNN4
SCHEMBL4137368 0.76 HSD11B1 (0.56) HSD11B1GAAMEN1ALDH1A1KMT2A
SCHEMBL4130981 0.75 HSD11B1 (0.57) HSD11B1GAAMEN1ALDH1A1KMT2A
SCHEMBL4136419 0.74 HSD11B1 (0.56) HSD11B1GAAMEN1ALDH1A1KMT2A
SCHEMBL4141023 0.74 HSD11B1 (0.56) HSD11B1GAAMEN1ALDH1A1KMT2A
SCHEMBL4137361 0.73 MAPT (0.44) HSD11B1GAAALDH1A1KMT2ADAO
SCHEMBL4143969 0.73 HSD11B1 (0.55) HSD11B1GAAMEN1ALDH1A1KMT2A
SCHEMBL4137544 0.73 HSD11B1 (0.54) HSD11B1GAAMEN1ALDH1A1KMT2A
SCHEMBL10774237 0.62 ACP3 (0.40) ACP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090156644-A1 Use of thiazole derivatives and analogues in the treatment of cancer BETAGENON AB (SE) 2009-06-18 US disclosed
US-20090136472-A1 Use of thiazole derivatives and analogues in disorders caused by free fatty acids BETAGENON AB (SE) 2009-05-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156644-A1 Use of thiazole derivatives and analogues in the treatment of cancer TBXA2R, TSHR, FOLR1 HSD11B1 1506/4885GAA 2671/4885MEN1 645/4885
US-20090136472-A1 Use of thiazole derivatives and analogues in disorders caused by free fatty acids FFAR2, FFAR1, FFAR4 HSD11B1 218/4885GAA 1211/4885MEN1 2016/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.